Oxford Instruments (OXIG) Q2 2027 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 TU earnings summary
13 Oct, 2026Group trading
H1 FY27 order intake rose nearly 44%; reported revenue increased ~8% (9% OCC), and adjusted operating margin is expected to improve by over 100 bps YoY.
Order intake and H2 orderbook cover underpin confidence in FY27 results in line with market expectations: revenue £444.4m and adjusted operating profit £81.0m.
Imaging and analysis
H1 order intake rose over 11% YoY, driven by semiconductor and materials science demand; divisional orderbook grew ~5% versus H1 FY26.
Revenue grew ~2–3% as smaller product lines replenished orderbook after high Q4 FY26 deliveries; full-year revenue growth remains expected in line with guidance.
Adjusted operating margin improved after a challenging H1 FY26, alongside continued investment and management of macro execution risks.
Advanced technologies
H1 order intake rose over 125% YoY; around three quarters came from datacom demand following commercial volume manufacturing customer wins.
Orderbook extends well into FY28, with expected FY27 revenue fully covered; H1 revenue grew ~26% as production capacity expanded.
Adjusted operating margin materially improved YoY despite increased investment in capacity expansion.
Latest events from Oxford Instruments
- Order growth and margin gains in H2 set the stage for accelerated FY27 expansion.OXIG
H2 2026 - Strong order growth and resilient H2 performance support a positive outlook for the next year.OXIG
Q4 2026 TU - Strong order growth and capital actions support full-year profit outlook.OXIG
Q3 2026 TU - Order recovery and cost actions set stage for stronger H2 after a challenging first half.OXIG
H1 2026 - H1 order intake rose 1% OCC, but revenues fell 8% OCC; full-year outlook remains stable.OXIG
H1 2026 TU - Revenue up 10% at constant currency, but currency headwinds to impact reported profit.OXIG
Trading Update - Strong 10.4% revenue growth and robust order book drive positive full-year outlook.OXIG
H1 2025 - Record revenue, margin expansion, and NanoScience divestment drive strong outlook.OXIG
H2 2025 - Revenue up 9.8%, margin target above 20%, with strong growth and strategic transformation.OXIG
H2 2024